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Abstract: Dysbiosis has been described in systemic autoimmune diseases (SADs), including systemic
lupus erythematosus (SLE), Sjögren’s syndrome (SjS), and primary anti-phosholipid syndrome (PAPS),
however the biological implications of these associations are often elusive. Stool and plasma samples
from 114 subjects, including in SLE (n = 27), SjS (n = 23), PAPs (n = 11) and undifferentiated connective
tissue (UCTD, n = 26) patients, and geographically-matched healthy controls (HCs, n = 27), were
collected for microbiome (16s rRNA gene sequencing) and metabolome (high-performance liquid
chromatography coupled to mass spectrometry) analysis to identify shared characteristics across
diseases. Out of 130 identified microbial genera, a subset of 29 bacteria was able to differentiate study
groups (area under receiver operating characteristics (AUROC) = 0.730 ± 0.025). A fair classification
was obtained with a subset of 41 metabolic peaks out of 254 (AUROC = 0.748 ± 0.021). In both models,
HCs were well separated from SADs, while UCTD largely overlapped with the other diseases. In all of
the SADs pro-tolerogenic bacteria were reduced, while pathobiont genera were increased. Metabolic
alterations included two clusters comprised of: (a) members of the acylcarnitine family, positively
correlating with a Prevotella-enriched cluster and negatively correlating with a butyrate-producing
bacteria-enriched cluster; and (b) phospholipids, negatively correlating with butyrate-producing
bacteria. These findings demonstrate a strong interaction between intestinal microbiota and metabolic
function in patients with SADs.
Keywords: microbiomic; metabolomics; systemic autoimmune diseases; systemic lupus erythematosus;
Sjögren’s syndrome; primary anti-phosholipid syndrome; undifferentiated connective tissue diseases
1. Introduction
Gut microbiota contributes to immune system development and to immune defense processes
involving both innate and adaptive immunity [1–4]. Specific gut bacterial phylotypes are involved in
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immune tolerance processes, including the activation of T regulatory cells through the production of
short chain fatty acid (SCFA) [5–7].
Investigations of the intestinal microbiome in patients with systemic autoimmune diseases (SADs)
have demonstrated a reduction of pro-tolerogenic bacterial species [8–11]. However, the functional
consequences of dysbiosis in SADs remain elusive. Few studies have investigated the intestinal
microbial profile in SADs from a multi-omic perspective by integrating microbiome and metabolome
data to provide insight into the functional characteristics of microbiota in these disease states [11–13].
A microbiome analysis in patients with systemic lupus erythematosus (SLE) showed a reduction
of intestinal microbial biodiversity and an altered SCFA production [9]. In mouse models of SLE,
the administration of antibiotics to counteract dysbiosis ameliorated SLE-related symptoms [14].
Recently, Enterococcus gallinarum was increased in SLE mice and found to be associated with an
increased gut epithelium permeability [15]. Metabolomic signatures have been investigated in a limited
number of SLE studies. The most consistent alterations were found in unsaturated fatty acids and
acyl-carnitines, as well as in phospholipid metabolites [16,17].
Very few studies have explored gut microbiota or serum metabolites in Sjögren’s syndrome
(SjS) [18,19]. In a study conducted on 42 SjS and 35 healthy controls, patients with SjS had an increased
prevalence of gut dysbiosis compared with controls and the extent of dysbiosis was correlated with
disease severity [20]. Among the metabolomic studies in SjS performed in comparison with SLE or RA
subjects, no definite conclusion on SjS metabolic fingerprints could be drawn from these works [17,21].
Various hypotheses on the pathogenesis of primary antiphospholipid syndromes (PAPs) have been
formulated. The potential molecular cross-reactivity between autoantigens and repeated sequences of
bacterial peptides has been hypothesized to stimulate T-cell mediated responses and B cell production
of specific PAPs auto-antibodies. Intestinal microbiota could potentially serve as the source of bacteria
stimulating a chronic systemic inflammatory response [22]. To our knowledge, only one study has been
performed investigating the intestinal microbiota in PAPS patients, and this study found a reduction of
Slackia strains (which are able to produce phospholipids including cardiolipin) and of Butyricides
(pro-tolerogenic bacteria) [23]. The only metabolomic analysis conducted so far identified abnormalities
associated with the metabolism of methyl group donors, ketone bodies, amino acids, and PAPS [24].
To date, there are still no clear guidelines and no recent studies on undifferentiated connective
tissue disease (UCTD) [25] that examine the pathogenic aspects of this condition. Consequently, neither
intestinal microbiota nor plasma metabolome analysis have been performed in this group of patients.
The present study investigated the intestinal microbiome and plasma metabolome in patients
with distinct SADs, including SLE, SjS, PAPS, and UCTD. We hypothesized that SADs may share
common microbiota features across disease states that contrast with microbiota features of healthy
controls (HCs).
2. Methods
2.1. Patients and Controls
A total of 114 subjects were enrolled in the study, including 27 SLE, 23 SjS, 11 PAPs, and 26 UCTD
patients, plus 27 ethnically-, age-, and sex-matched HCs. All of the patients were recruited at the Referral
Center for Systemic Autoimmune Diseases, Fondazione Istituto Ricerca a Carattere Scientifico (IRCCS)
Ca’ Granda Ospedale Maggiore Policlinico of Milan, and at the Department of Rheumatology, Azienda
Scocio Sanitaria Territoriale (ASST) Istituto Gaetano Pini and Centro Traumatologico Ortopedico (CTO)
of Milan. SLE patients fulfilled the 1997 update of 1982 American College of Rheumatology criteria [26].
SjS patients fulfilled the American European Consensus Group (AECG) SjS classification criteria [27].
PAPs patients fulfilled the international consensus statement on an update of the classification criteria
for definite PAPs [28] and UCTD were defined as those subjects with clinical features of SADs fulfilling
none of the above criteria nor any other SADs criteria for at least 2 years, plus the presence of antinuclear
antibodies (ANA) ≥ 1:160 with or without SAD-specific autoantibodies.
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Clinical and laboratory characteristics of patients were recorded in the PRECISESADS case report form
and later extracted for the present study. Autoantibodies were centrally determined at the Laboratory of
Immunology and Immunotherapy of the Université Bretagne Occidentale (UBO) via a chemiluminescence
autoantibody screening strategy using the IDS-iSYS immunoanalyzer (Boldon, UK) and coated magnetic
particles (solid phase) coupled with autoantigens (Technogenetics, Milan, Italy). Polyclonal human
rheumatoid factors (RF), complement C3c, C4, were measured using a turbidimetric immunoassay
(SPAPLUS® analyzer, The Binding Site, Grassobbio, Italy).
Our research is ancillary to the PRECISESADS project (https://clinicaltrials.gov/ct2/show/
NCT02890121) that was approved by the local ethics committee (Comitato Etico Area 2, Milano;
approval no. 425bis dated Nov 19, 2014, and no. 671_2018 dated Sep 19, 2018).
2.2. Collection and Storage of Samples
Patients donated stool samples and within 24 hours of the stool collection the plasma samples
were obtained for metabolomic analysis and for autoantibody determination (see above). None of the
patients were treated with antibiotics or probiotics within 4 weeks of the collection of fecal samples,
which were frozen at −20 ◦C until delivery to the laboratory of probiogenomics of Parma University
for processing and analysis. Plasma samples were frozen at −80 ◦C until delivery to the University of
Granada for metabolomic analysis.
2.3. 16S rRNA Gene-Sequencing
DNA was extracted from each stool sample using DNA extraction using the QIAamp DNA Stool
Mini kit following the manufacturer’s instructions (Qiagen).
Partial 16S rRNA bacterial gene sequences were amplified from extracted DNA using primer pair
Probio_Uni/Probio_Rev, which target the V3 region of the 16S rRNA gene sequence 16S rRNA. Gene
amplification and amplicon checks were carried out as previously described [29]. Notably, the primer
pair Probio_Uni/Probio_Rev was specifically developed to maximize coverage and amplification
performance of gut bacterial populations. The 16S rRNA gene sequencing was performed using
a MiSeq Illumina at the DNA sequencing facility of GenProbio srl [30] according to the protocol
previously reported. Following sequencing and demultiplexing, the reads of each sample were filtered
to remove low quality and polyclonal sequences and data were exported as fastq files. The fastq
files were processed using a custom script based on the QIIME software suite [31]. Paired-end reads
pairs were assembled to reconstruct the complete Probio_Uni/Probio_Rev amplicons. Quality control
retained those sequences with a 140–400 bp length and mean sequence quality score > 20. Sequences
with homopolymers > 7 bp and mismatched primers were omitted. Chimeric sequences were removed
with ChimeraSlayer included in the quantitative insights into microbial ecology (QIIME) 2 software
suite (http://qiime.org/). To calculate downstream diversity measures, 16S rRNA operational taxonomic
units (OTUs) were defined at ≥ 97% sequence homology using uclust and OTUs with < 10 sequences
were filtered [32]. All reads were classified to the lowest possible taxonomic rank using QIIME and the
SILVA database v. 119 clustered at 97% identity as the reference dataset [33].
2.4. Metabolomic Analysis in Plasma
Plasma samples were thawed on ice, then an aliquot of 100 µL of each sample was mixed with
200 µL of methanol:ethanol (50:50, v/v) to remove proteins [34]. The solutions were vortex-mixed
and kept at −20 ◦C for 30 min to achieve an efficient protein precipitation and to avoid possible
sample degradation. Subsequently, the samples were centrifuged (4 ◦C, 10 min, 18,400 × g), and the
supernatants were evaporated in a vacuum concentrator for 105 min. The dry residue was reconstituted
in 100 µL of 0.1% aqueous formic acid:methanol (95:5, v/v), and centrifuged in the same conditions
mentioned previously to remove the solid particles. Finally, a 40 µL aliquot was transferred to high
performance liquid chromatography (HPLC) vials and stored at −80 ◦C before their analysis. A quality
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control (QC) sample was created by mixing equal volumes of each sample (20 µL) and treated as
described above.
2.5. HPLC-ESI-QTOF-MS Analysis
For the detection of metabolic peaks, a quadrupole-time of flight mass spectrometry analyzer
(QTOF-MS) was used coupled to high performance liquid chromatography (HPLC). Specifically,
an Agilent 1260 HPLC system (Agilent Technologies, Palo Alto, CA, USA) was used together with
an Agilent 6540 Ultra High Definition (UHD) Accurate Mass Q-TOF system (Agilent Technologies,
Palo Alto, CA, USA) equipped with a dual-stream Electrospray Ionization (ESI) interface.
The compounds were separated in a C18 reverse phase analytical column (Agilent Zorbax Eclipse
Plus, 3.5 µm, 2.1 × 150 mm). The mobile phases were made up of water plus 0.1% formic acid
and methanol as solvents A and B, respectively. To obtain an efficient separation of the metabolites,
the following gradient of mobile phases was applied: 0 min (A:B, 95/5), 5 min (A:B, 90/10), 15 min (A:B,
15/85), 32–40 min (A:B, 0/100), and 45 min (A:B, 95/5).
A QC sample was analyzed every 5 real samples in order to check the analytical reproducibility
and correct possible analytical drifts during the sequence. In addition, a tandem mass spectrometry
analysis (MS/MS) of the QC sample was performed to obtain characteristic fragments of molecular
species that help in the identification process of candidate metabolites. This experiment was conducted
using nitrogen as collision gas with different energy values (10, 20, and 40 eV).
A recursive feature extraction for small molecules was performed on the analyzed samples using
the MassHunter Profinder software (B.06.00, Agilent). Peaks were filtered with an intensity threshold
of 1000 counts; [M + H]+, [M + Na]+ and [M + H − H2O]+ were the considered adducts. The retention
times and masses between the different samples were aligned with thresholds of ± 0.25 min and
40 ppm ± 4 mDa, respectively. The exported areas were normalized by the MS total useful signal
(MSTUS) [35].
2.6. Statistical Analysis
2.6.1. Canonical Analysis of Microbiota
The biodiversity of samples (alpha diversity) was calculated with the Chao1 and Shannon indices
using 10 subsampling points for a maximum of 54,890 sequences in order to generate rarefaction curves.
Similarities between samples (beta diversity) were calculated by unweighted uniFrac. [36]. Principal
coordinate analysis (PCoA) representations of beta diversity were performed using QIIME [31].
For the other analyses, bacteria at the genus taxonomic rank, with an overall abundance >1%,
were considered.
2.6.2. Data Mining Classification and Non-Linear Interactions Analysis
To model nonlinear multivariate interactions among variables, several inductive data mining
algorithms were used. The overall procedure is described in detail in [11]. Briefly, the study pipeline
included a 5-fold nested cross-validation phase (to perform model selection and data filtering) in the
context of a repeated (10x) 5-fold cross-validation phase (to assess the robustness and capability of
generalization of the selected model). In the model-selection phase, 5 different inductive algorithms
were tested: naive Bayes, ada boost (500 runs), random forest (500 runs), extra trees classifiers (500 runs),
or voting classifier (soft voting of the 4 previous algorithms). A stochastic hill climbing procedure
was used to select the subset of attributes that in the nested cross-validation phase globally optimized
one-vs.-one comparisons. The balanced accuracy (BA), which is the average of sensitivity and specificity,
was used as the fitness function for modelling and feature selection. Results in the validation phase are
expressed as BA, F1 measure (harmonic mean between sensitivity and precision/positive predictive
value), and area under receiver operating characteristics (AUROC). BA, F1, and AUROC are presented
as the weighted mean of all the possible pairwise comparisons.
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In each training fold data were preprocessed, standardizing data values and removing 5% of the
outliers via the isolation forest method (500 trees). For the microbiome dataset, genera with values
equal to zero in > 95% of the cases were removed.
To graphically represent multidimensional results we used the FreeViz method [37]. This method
selects, via a gradient descent algorithm, the representation that optimizes the compactness and
separation of instances of the same class, as assessed by average silhouette scores [38].
A subanalysis comparing the overall anti Ro60/SSA positive versus anti Ro60/SSA negative
patients was conducted with the same procedures described above.
2.6.3. Post-Hoc Statistical Analysis on Classification Data
Selected bacterial genera and metabolomic peaks were compared between study groups by
Kruskal–Wallis tests and if significant after false discovery rate (FDR) correction at the nominal 0.05
alpha level, the Dunn test was performed for post-hoc analysis.
2.6.4. Cross-Correlation Analysis
In patients with SADs, microbial genera (G) were correlated with metabolites (M) correcting
for potential confounding variables at the time of sampling: age, the use of hydroxycloroquine
(yes/no), the use of prednisone > 5 mg/day (yes/no), and the use of immunosuppressants (any type,
yes/no). To this end, a partial correlation analysis was performed considering plasma metabolites as
dependent (Y) variable, microbial genera as independent variable (Z), and the confounding variables
as covariates (X). To test the null hypothesis of no relationship between Y and Z over and above any
relationship of Y with X, we calculated the Pearson’s r coefficient using the residuals RY|X (residuals
of regression equation of Y on X alone) and RZ|X (residuals of regression equation of Z on X alone).
The procedure was iteratively repeated to produce a G x M cross-correlation matrix. The significance
of matrix entries were calculated and corrected for multiple testing using a stepwise pMin procedure
randomly permuting raw data (Y variable); 10,000 random runs were used to this end [39,40].
Partial r values in the G x M cross-correlation matrix were used to cluster genera and metabolites
by means of the hierarchical clustering and Wards linkage methods and manually inspecting the cluster
tree. The average (centroid) relative abundances and peak areas from clustered genera and metabolites
were calculated for each individual; centroids were then used to build a simplified cross-correlation
matrix. Correlation data were corrected for confounding variables taking into account multiple testing
as described above.
For all of the analyses, custom codes written in python by L. B. built on top of the scikit-learn
modules [41] were used; codes are available upon request. Clusters were built with the Orange data
mining suite (https://orange.biolab.si/).
3. Results
Clinical and demographic characteristics of the study participants are reported in Table 1. SADs
patients were mostly female, whereas a slightly higher proportion of males was observed in HCs.
Physician global assessment scale was similar in the 4 groups of SADs, with a slight increase in
PAPs patients. All four disease groups had an average prednisone intake of less than 10 mg per day.
Prevalent clinical features and autoantibody specificities were consistent with the baseline diagnosis.
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Table 1. Demographic and clinical characteristics of study participants.
SLE
(n = 27)
SjS
(n = 23)
PAPS
(n = 11)
UCTD
(n = 26)
HC
(n = 27)
Age, mean (SD) 47.70 (16.55) 65.91 (12.72) 40.36 (6.17) 52.23 (12.01) 52.47 (9.96)
Females, n (%) 24 (88.9) 22 (95.65) 8 (72.72) 23 (88.46) 20 (74.07)
Disease duration years, mean (SD) 15.16 (10.92) 9.95 (9.38) 11.17 (5.92) 9.43 (5.09) -
AutoAb profile, n (%)
ANA 27 (100) 20 (86.97) 2 (16.67) 26 (100)
Anti-Ro 60/SSA 4 (14.81) 15 (65.22) 0 (0) 3 (11.53)
Anti-La/SSB 1 (3.70) 10 (43.48) 0 0
Anti dsDNA 13 (48.14) 0 (0) 2 (18.18) 5 (19.23)
Anti Sm 2 (7.4) 0 (0) 0 (0) 0 (0)
ACL 0 (0) 0 (0) 6 (54.54) 1 (3.85)
Anti B2GP 1 (3.70) 0 (0) 8 (72.72) 1 (3.85)
RF 1 (3.70) 11 (47.83) 0 (0) 3 (11.54)
C3c mg/dL, mean ± SD 82.7 ± 21.6 101.8 ± 25.3 100.1 ± 21.2 101.3 ± 28.9
C4 mg/dL, mean ± SD 14.6 ± 7.2 19.1 ± 8.8 16.9 ± 9.1 16.6 ± 6.2
Abnormal Liver function, n (%) 4 (14.81) 1 (4.35) 0 (0) 2 (7.69) -
GERD, n (%) 5 (18.51) 11 (47.83) 1 (9.09) 10 (38.46) -
Pericarditis, n (%) 4 (14.81) 0 (0) 0 (0) 0 (0) -
Hypertension, n (%) 6 (22.22) 2 (8.69) 2 (18.18) 5 (19.23) -
Valve lesions, n (%) 1 (3.70) 1 (4.35) 1 (9.09) 1 (3.85) -
Dyslipidemia, n (%) 5 (18.51) 2 (8.69) 3 (27.27) 3 (11.54) -
Abnormal creatinine, n (%) 7 (25.92) 1 (4.35) 2 (18.18) 3 (11.54) -
Abnormal urine, n (%) 10 (37.03) 1 (4.35) 3 (27.27) 2 (7.69) -
Proteinuria, n (%) 7 (25.92) 1 (4.35) 3 (27.27) 0 (0) -
Anemia past, n (%) 3 (11.1) 1 (4.35) 0 (0) 0 (0) -
Low platelet count, n (%) 8 (29.62) 2 (8.69) 2 (18.18) 1 (3.85) -
Low WBC, n (%) 18 (66.67) 6 (26.09) 2 (18.18) 7 (26.92) -
Pleuritis, n (%) 1 (3.70) 1 (4.35) 0 (0) 0 (0) -
Arthritis, n (%) 17 (62.96) 3 (13.04) 1 (9.09) 6 (23.08) -
Myopathy, n (%) 2 (7.4) 0 (0) 0 (0) 0 (0) -
CNS involvement, n (%) 3 (11.1) 1 (4.35) 4 (36.36) 0 (0) -
PNS involvement, n (%) 0 (0) 0 (0) 2 (18.18) 1 (3.85) -
Mucositis, n (%) 10 (37.03) 0 (0) 2 (18.18) 4 (15.38) -
Cutaneous active lupus, n (%) 19 (70.37) 1 (4.35) 1 (9.09) 2 (7.69) -
Cutaneous chronic lupus, n (%) 5 (18.51) 0 (0) 1 (9.09) 4 (15.38) -
Photosensitivity, n (%) 22 (81.48) 2 (8.69) 1 (9.09) 13 (50) -
Puffy fingers, n (%) 2 (7.4) 0 (0) 0 (0) 0 (0) -
Sicca, n (%) 12 (44.44) 21 (91.30) 1 (9.09) 9 (34.62) -
Inflammation, n (%) 17 (62.96) 10 (43.48) 1 (9.09) 13 (50) -
PGA, mean (SD) 28.52 (21.61) 30.78 (18.97) 47.27 (29.44) 30.28 (18.2) -
Fever, n (%) 0 (0) 2 (8.69) 1 (9.09) 2 (7.69) -
Hypergammaglobulinemia, n (%) 12 (44.44) 12 (52.17) 0 (0) 9 (34.62) -
Venous thrombosis, n (%) 2 (7.4) 0 (0) 6 (54.54) 1 (3.85) -
Raynaud’s phenomenon, n (%) 8 (29.62) 2 (8.69) 1 (9.09) 11 (42.3) -
Miscarriage, n (%) 2 (7.4) 1 (4.35) 7 (63.63) 0 (0) -
Statin use, n (%) 2 (7.4) 2 (8.69) 1 (9.09) 2 (7.69) -
Prednisone (>5 mg/day), n (%) 7 (25.92) 3 (13.04) 1 (9.09) 9 (34.62) -
Prednisone dose, mean mg/day 7.55 8.62 7 5.67 -
HCQ use, n (%) 19 (70.37) 9 (39.13) 8 (72.72) 13 (50) -
Immunosuppressant use, n (%) 10 (37.04) 2 (8.69) 0 (0) 3 (11.54) -
Note: SLE, systemic lupus erythematosus; SjS, Sjogren’s syndrome; PAPS, primary antiphospholipid syndrome; UCTD,
undifferentiated connective tissue disease; HC, healthy controls; SD, standard deviation. ANA, anti-nuclear antibodies;
anti-Ro60/SSA and anti-La/SSB, anti-Sjögren’s-syndrome-related antigen A and B; anti dsDNA, anti-double stranded
DNA; anti Sm, anti-Smith antibodies; ACL, anti-cardiolipin antibodies; anti B2GP, anti-beta2glicoprotein-I antibodies;
RF, rheumatoid factor; GERD, gastro-esophageal reflux; WBC, white blood cells; CNS, central nervous system; PNS,
peripheral nervous system; PGA, physician’s global assessment scale; HCQ, hydroxychloroquine. For clinical data the
occurrence of symptom in the medical history (“ever”) is counted as an entry. For therapies, the current use is listed.
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3.1. Microbiomic Analysis
After performing microbiome quality filtering (Supplementary File 1), our alpha diversity analysis
found no differences either in richness or in evenness of taxa among the study groups (Supplementary
Figure S1). Similarly, principal coordinate analysis (PCoA) analysis of beta diversity could not separate
any disease from the others, albeit HCs tended to cluster apart from SADs (Supplementary Figure S2).
On the contrary, classification algorithms discriminated the different diseases with AUROC = 0.727 ± 0.034,
F1 = 0.704± 0.024, and BA = 0.654± 0.018 when all of the genera were considered. A similar discrimination
could be obtained after feature selection, highlighting the importance of selecting a subset of bacteria in
differentiating the different classes: AUROC = 0.730 ± 0.025, F1 = 0.717 ± 0.034, and BA = 0.663 ± 0.031.
The final model included 29 genera (Supplementary Table S1) and almost completely separated HCs from
SADs, as shown in Figure 1; the capability of this subset of bacteria to differentiate the SADs and HCs
(pairwise comparisons) according to the different classification metrics is represented in Supplementary
Figure S3. According to FreeViz representation, HCs emerged as an isolated cluster, while UCTD patients
had the highest degree of overlap with the other autoimmune diseases.
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Figure 1. Clustering of selected microbiome genera. Visual representation by FreeViz projections
of selected microbiome genera that best maximize the global pairwise goodness of fit (mean of all
the possible one-vs.-one comparisons). The graphical representation is optimized to maximize the
compactness and separation of clusters as measured by silhouette scores. Note: Red = healthy controls;
purple = systemic lupus erythematosus; green = Sjogren’s syndrome; blue = primary antiphospholipid
syndrome; yellow = undifferentiated connective tissue disease. Shaded areas indicate 99%, 95%, and
90% confidence ellipse intervals (from darkest to lightest).
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Univariate analysis showed that the abundance of some genera was statistically different in SADs
compared to HCs. Namely, the abundance of Bifidobacterium, Ruminiclostridium, Streptococcus, U. m.
of Coriobacteriaceae family, U. m. of Enterobacteriaceae family, and Collinsella was significantly lower
in the HCs group compared to the other groups (Supplementary Figure S4), while the abundance of
Lachnoclostridium, Lachnospira, and Sutterella was significantly increased in HCs compared to SLE, SjS,
PAPs, and UCTD (Supplementary Figure S5).
The subanalysis of microbiome comparing anti Ro60/SSA positive versus anti Ro60/SSA negative
patients did not show significant results (BA and AUROC < 0.6).
3.2. Metabolomic Analysis
Feature selection in our metabolomic analysis slightly reduced the original fit of the complete
model. A reduced model comprised of 41 metabolites was capable of performing a fair joint pairwise
classification of diseases with an AUROC = 0.748 ± 0.021 (vs. 0.766 ± 0.015 of the full model),
F1 = 0.684 ± 0.015 (vs. 0.702 ± 0.023), and BA = 0.671 ± 0.013 (vs. 0.674 ± 0.02). The selected significant
peaks are detailed in Supplementary Table S2, while their multidimensional representation is illustrated
in Figure 2. The metabolites were identified by the comparison of the MS results (mass exact, isotopic
distribution, and MS/MS fragments) and the information from the metabolomic databases. However,
despite the efforts in the identification, a number of peaks remained unknown because this stage is
currently the bottleneck in the field of metabolomics [42]. Pairwise comparisons are illustrated in
Supplementary Figure S6, in which select metabolites could discriminate HCs from SADs, while their
performance in SAD-to-SAD comparisons was less remarkable.
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Figure 2. Clustering of selected metabolites. Freeviz representations of selected metabolites (see legend
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A number of peaks were differentially distributed in the analyzed groups according to univariate
statistical analysis, as highlighted in Supplementary Table S2. Not surprisingly, most of the differences
were due to reduced or increased normalized peak area values in HCs compared to one or more
disease groups.
The analysis in anti-Ro60/SSA positive versus anti-Ro60/SSA negative patients showed that the
two groups could weakly, albeit non-substantially be distinguished from the metabolic point of view
(average AUROC = 0.689; BA = 0.569).
3.3. Cross-Correlation Analysis
Supplementary Figure S7 represents the cross-correlation matrix corrected for age and concurrent
therapies among microbial genera and metabolites; correlations significant at the 0.05 threshold after
permutation test and with an absolute Pearson’s r > 0.3 are highlighted. According to partial correlation
coefficients, we could distinguish 7 bacterial and 9 metabolite clusters. Data aggregation of individual
data within these clusters yielded the simplified cross-correlation matrix illustrated in Figure 3.
Attempts were made to identify metabolites within the clusters yielding the most significant partial
correlation values. We could observe an enrichment of specific metabolites within each cluster: Cluster 1:
Acylcarnitines; Cluster 2: Caffeine/Tryptophan; Cluster 3: mixed; Cluster 4: Kynurenine/Phenylalanine;
Cluster 5: Aminoacids; Cluster 6: phosphatidylcholine (PC) and sphingomyelin (SM); Cluster 7: Fatty
acids and tryglicerides (TG) and PC; Cluster 8: phosphatidylserine (PS) and PC; Cluster 9: LysoPC.J. Clin. Med. 2019, 8, x FOR PEER REVIEW 10 of 15 
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metabolome data after correction for confounding variables (age, hydroxycloroquine, steroid and
immunosuppressant use). Aggregated clusters are calculated from the full correlation matrix
shown in Supplementary Figure S7, as described in the methods and manually annotated. Note:
Diamonds, positive partial correlations; circles, negative partial correlations; p values assessed after
permutation testing.
4. Discussion
To our knowledge, this is the first study to investigate and compare the gut microbiota and plasma
metabolome profiles of 4 distinct SADs (SLE, SjS, UCTD and PAPS). Instead of focusing on specific
alterations that may explain putative differences between HCs and single diseases, we tried to discover
a common set of alterations jointly capable of discriminating SADs from HCs. Albeit with individual
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differences, our findings indicate that SADs share similar etiologic factors and pathophysiological
mechanisms similar to the common genetic background or similar epigenetic processes that have been
described in these disease states [43]. Among the analyzed SADs, the microbiota and metabolome
profiles of patients with UCTD overlapped with other disease groups, likely due to the fact patients
with this phenotype have nonspecific clinical features of the other SADs under study [44].
In terms of specific microbial findings, we observed an increased relative abundance of Bifidobacterium,
Ruminiclostridium, Streptococcus, U. m. of Coriobacteriaceae family, and U. m. of Enterobacteriaceae family in
all of the SADs compared to HCs. Bifidobacterium is known to be increased in active phase of inflammatory
bowel disease [45]; similarly, Streptococcus has been associated with inflammatory intestinal conditions [46].
Taxa belonging to the order of Clostridiales (i.e., Ruminiclostridium) have been found in lower abundance in
Crohn’s disease. In murine models of RA, the expansion of Clostridiales was correlated with transcription
of pro-inflammatory cytokines (Th1/Th17) [47]. Similarly, a high relative abundance of Streptococcus
has been associated with relapsing-remitting multiple sclerosis and increased Th17 cell frequency [48].
Interestingly, in our SLE and PAPS subjects, we noticed an increased relative abundance of Collinsella,
another taxon, which was increased in RA patients and correlated with IL-17a [49].
Conversely, we found a reduction of Lachnoclostridium, Lachnospira, and Sutterella in all SADs
groups compared to HCs. Lachnoclostridium and Lachnospira are part of Lachnospiraceae, a family of
bacteria capable of producing SCFA (such as butyric acid) with a highly pro-regulatory, tolerogenic
role on immune functions [50]. Our results are, thus, aligned with several previous observations of
a depletion in tolerogenic bacteria in patients affected by SADs [9,10,47].
Consistent with our microbiomic findings, the metabolomic analysis revealed that SADs had
unique metabolomic features distinguishing them from HCs. A relatively small subset of peaks (n = 41)
was able to maximize the discrimination among groups. Despite the observation that some metabolites
were differentially represented in selected SADs compared to HCs, a unifying discriminative pattern
could not be identified. These findings highlight the complex interaction among metabolites in SADs
and underline that several metabolic pathways may be non-linearly involved in their phenotypic
expression. Our results are in accordance with Bengtsson et al., where very few metabolites withstand
statistical correction, yet provide a good separation between SjS and HCs or SLE, and to a lesser extent
between SLE and HCs when jointly considered [17]. Of interest, among the annotated peaks in our
reduced classification model we could identify several members of the acylcarnitine family, suggesting
a deregulation of β-oxidation processes in SADs, as already suggested in RA, SLE, or SjS [17,51–54].
As a confirmation of the concordant behavior of the microbiomic and the metabolomic profile
observed by our data mining analysis, we observed a moderate-to-strong correlation among selected
individual metabolic peaks and bacterial genera. Although a causal relationship cannot be established
by this kind of analysis, we could extract some metabolite and bacterial clusters that correlated with
each other. In particular, a cluster enriched by acylcarnitine metabolites was significantly directly
correlated with a group mostly represented by Prevotella genera. In support of this correlation, a dietary
intake of carnitine has been implicated in trimethylamine N-oxide (TMAO) production, an amine
oxide obtained from carnitine, betaine, and choline through gut microbiota metabolism. Bacterial
families implicated in TMAO production include Enterobacteriaceae and Prevotellaceae [55]. Koeth et al.
found a significant increase in plasma TMAO related to an enterotype rich in Prevotella and peculiar of
omnivore subjects [56].
On the contrary, an inverse correlation between the acylcarnitine family cluster and a cluster
of bacteria mainly composed of butyrate-producing strains was found. This cluster includes
Anaerostipes, Subdoligranulum, Intestinimonas and Flavonifractor [57], Eisenbergiella [58], Megamonas [59],
and Cloacibacillusg [60]. Butyrate-producing bacteria are immunologically pro-tolerogenic strains that
metabolize SCFA mostly obtained from fruits and vegetables, while on the contrary carnitine intake
from diet derives mostly from red meat. Additionally, we also found an inverse correlation between
a PC-enriched cluster and the butyrate-producing, bacteria-enriched cluster. In complex experiments
and putative explanatory models, butyrate was shown to upregulate cytosolic phospholipase A2
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(PLA2) activity in macrophages and secretory PLA2 activity in adipocytes and macrophages to
ultimately suppress lipolysis [61]. As lipolysis participates in inflammatory signaling processes,
we may hypothesize that in SADs the (loss) of butyrate-producing bacteria may influence inflammation,
disrupting PC and lysoPC homeostasis [62,63].
While a number of results from our study are intriguing, we shall acknowledge some drawbacks
of our work. Mechanistic studies on animal models would be a fundamental integration of the
observed data to better define the functional role of identified bacteria. Moreover, even if the overall
number of enrolled patients is satisfactory and unprecedented in SADs studies, there is a lack of
homogeneity because PAPs are underrepresented compared to the other. Geographical implications on
microbiome and metabolome results should also be taken into account and we cannot guarantee that
our findings are generalizable to genetically diverse populations with different lifestyles and dietary
habits. Lastly, a thorough analysis comparing patents with different autoantibody subsets could have
provided additional microbiomic and metabolomic information. It is known that the presence of specific
autoantibodies may be more informative than the clinical phenotypic stratification [64,65] and may
have omic implications as well [66,67]. Unfortunately, despite our attempts, the subanalysis based on
Ro60/SSA specificity yielded inconclusive results, most likely due to the inadequate number of patients
and to the unbalanced nature of data. As such, more focused and powerful studies are required to solve
this issue.
5. Conclusions
Our findings indicate that SLE, UCTD, SjS, and PAPS patients share common intestinal microbiome
and metabolomic profiles. Although specific causative explanations cannot be made, a correlation
between microbial genera and metabolites affirm the hypothesis that an interaction between intestinal
microbiota and metabolic function exists. These data indirectly support the notion that modulation
of microbiota, either by diet or by other means, may be a potential strategy to tackle the systemic
consequences of dysbiosis, including inflammation and autoimmunity [64,65]. The optimal strategy to
modulate dysbiosis in SADs remains elusive, yet the study of the metabolome appears to be a valuable
option to monitor the effect of such an intervention and warrants further research.
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